601 related articles for article (PubMed ID: 26387577)
21. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
[TBL] [Abstract][Full Text] [Related]
22. Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer.
Goyal RK; Tzivelekis S; Rothman KJ; Candrilli SD; Kaye JA
Support Care Cancer; 2018 Feb; 26(2):539-548. PubMed ID: 28921379
[TBL] [Abstract][Full Text] [Related]
23. Reducing febrile neutropenia rates in early breast cancer. Experience of two UK cancer centres.
Mullard AP; Misra V; Sumra P; Ali Z; O'Reilly SM; Malik Z
Support Care Cancer; 2014 Aug; 22(8):2033-7. PubMed ID: 24595405
[TBL] [Abstract][Full Text] [Related]
24. Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy.
Sulpher J; Giguere P; Hopkins S; Dent S
Support Care Cancer; 2016 Jul; 24(7):3185-9. PubMed ID: 26939922
[TBL] [Abstract][Full Text] [Related]
25. A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens.
Zardawi SJ; Nordman I; Zdenkowski N
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1266. PubMed ID: 32761893
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
Ramsey SD; Liu Z; Boer R; Sullivan SD; Malin J; Doan QV; Dubois RW; Lyman GH
Value Health; 2009; 12(2):217-25. PubMed ID: 18673353
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
[TBL] [Abstract][Full Text] [Related]
28. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
Fernandes R; Mazzarello S; Stober C; Vandermeer L; Dudani S; Ibrahim MF; Majeed H; Perdrizet K; Shorr R; Hutton B; Fergusson D; Clemons M
Breast Cancer Res Treat; 2017 Jan; 161(1):1-10. PubMed ID: 27783280
[TBL] [Abstract][Full Text] [Related]
29. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
31. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
32. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
Support Care Cancer; 2021 Jul; 29(7):3507-3512. PubMed ID: 33146835
[TBL] [Abstract][Full Text] [Related]
33. Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort study.
Kwok CCH; Wong WH; Chan LL; Wong SPY; Wang F; Wong MCS; Tse SLA
Hong Kong Med J; 2022 Dec; 28(6):438-446. PubMed ID: 36261264
[TBL] [Abstract][Full Text] [Related]
34. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
[TBL] [Abstract][Full Text] [Related]
35. Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.
Bacrie J; Laurans M; Iorio P; Fourme E; Volters AB; Bozec L; Lerebours F; Dubot C; Bensaoula O; Benzidane B; Pierga JY; Lefeuvre D
Support Care Cancer; 2018 Dec; 26(12):4097-4103. PubMed ID: 29855772
[TBL] [Abstract][Full Text] [Related]
36. TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
Eckhoff L; Nielsen M; Moeller S; Knoop A
Acta Oncol; 2011 Oct; 50(7):1075-82. PubMed ID: 21824038
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
Lyman G; Lalla A; Barron R; Dubois RW
Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
[TBL] [Abstract][Full Text] [Related]
38. Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy.
Ku M; Je NK
J Chemother; 2022 Dec; 34(8):534-542. PubMed ID: 34870568
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan.
Tseng TH; Chiang SC; Hsu JC; Ko Y
PLoS One; 2024; 19(6):e0303294. PubMed ID: 38857244
[TBL] [Abstract][Full Text] [Related]
40. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]